FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
← catalyst calendarSponsored by Fate Therapeutics (industry) · FATE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
20actual
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-16 | actual | When the study began enrolling |
| Primary completion | 2025-06-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-30 | actual | The whole study's end, after follow-up |
| First posted | 2023-07-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed/Refractory B-Cell Lymphoma
Interventions
- Drug: FT522
- Drug: Rituximab — also filed as RITUXAN, TRUXIMA, RUXIENCE, RIABNI
- Drug: Cyclophosphamide
- Drug: Fludarabine
- Drug: Bendamustine
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with dose limiting toxicities (DLTs)
measured From Day 1 through Day 29 of Cycle 1
Severity of DLTs
measured From Day 1 through Day 29 of Cycle 1
Permalink · FATE's whole pipeline · Catalyst calendar · Every registered study · What changed